Linda Clark, Health Care Controversies Team leader, and Brad Gallagher, counsel, recently had their “Caremark’s Bold Move to Restrict Dispensing and Access to Products on the Formulary” article published on the Pharmacy Insider blog.
“Suspect product” lists have been used for years by pharmacy benefit managers (PBMs) to target independent pharmacies and subject them to heightened scrutiny. These lists often target high margin products or other drugs that, for other unknown reasons, may be disfavored by PBMs without regard to formularies of individual plans. The lists are secret, and only “word-of-mouth” through the experiences of other network pharmacies do we learn of the targeted products or manufacturers.”
Read the full article here.